Emerging Markets

Identifying opportunities in emerging markets

Wednesday, February 1, 2017

A strong technological and scien­tific infrastructure, world-class medical facilities and government in­centives and support are just some of the advantages medical professionals should take into consideration when identifying new business locations globally. Innovation cannot thrive without these components.

[Read More]

Clinerion enters an improved clinical trials market in Brazil

Monday, January 16, 2017

In mid-December, Clinerion, a patient recruitment company, made its entrance into the clinical trials market in Brazil. With a state-of-the-art patient recruitment system (PRS) that has a track record of rapid identification of eligible patients in other markets, Clinerion is poised to make a significant difference in Brazil.

[Read More]

Slow to negative growth in select emerging markets

Tuesday, March 1, 2016

A few years ago, Latin America and India were considered among the most promising emerging markets for conducting industry-sponsored clinical trials. Dramatic increases were predicted for both regions, and investigative sites anticipated an influx of new work. Unfortunately, growth in these markets has fallen far short of expectations.

[Read More]

OrbiMed launches $222 million fund in Israel life sciences

Tuesday, April 24, 2012

OrbiMed, a global investment management firm focused on the healthcare sector, has closed its first investment fund dedicated to life sciences venture capital opportunities based in Israel. The Fund, OrbiMed Israel Partners Limited Partnership, includes an anchor investment provided by the government of Israel, which also provided special economic terms through the initial tender process for the Fund.

[Read More]

Russia’s cancer drug market to grow to $163 million

Wednesday, December 14, 2011

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

[Read More]